Nathan Gray
Subscribe to Nathan Gray's Posts
Nathan Gray is a member of the Healthcare Practice Group. While earning his law degree, Nathan served as a summer associate at McDermott. He was a legal fellow at Compassion and Choices in Portland, Oregon, and served as internal vice president of the Health Law Society at Duke University School of Law. Read Nathan Gray's full bio.
Pending California Law Undermines Growth of Digital Health Companies and Patient Access to Virtual Care
By Lisa Schmitz Mazur, Patrick Zanayed, Nathan Gray, Travis Jackson and Joel Rush on Aug 22, 2024
Posted In Digital Health, Employee Benefits, Health and Welfare Plans
In California, pending Assembly Bill 3129 could severely limit the ability of digital health companies to grow and operate in the state by prohibiting arrangements between physician, psychiatric, and dental practices and any entity that furnishes business or management services to providers that accept investments from private equity groups and hedge funds. The legislation’s current...
Continue Reading
FDA Pushes to Diversify Clinical Studies, Releases Draft Industry Guidance
By James Ravitz, Jennifer S. Geetter, Jiayan Chen, Paul Gadiock, Jeff Weinstein, Marissa Hill Daley, Nathan Gray and Karis Jackson on Aug 20, 2024
Posted In Employee Benefits, Health and Welfare Plans
On June 26, 2024, the US Food and Drug Administration (FDA) released its much-anticipated draft guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. The draft guidance provides valuable information about what steps the FDA will expect sponsors to take to promote adequate representation across demographic characteristics in...
Continue Reading
FDA Establishes CDER Center for Drug Innovation (C3TI)
By James Ravitz, Paul Gadiock, Jiayan Chen, Marissa Hill Daley, Nathan Gray and Karis Jackson on May 29, 2024
Posted In Employee Benefits, Health and Welfare Plans
On April 15, 2024, the US Food & Drug Administration (FDA) announced the establishment of the Center for Drug Evaluation and Research (CDER) Center for Clinical Trial Innovation (C3TI). C3TI will serve as the central support hub for innovative approaches to clinical trials designed to improve the quality and efficiency of drug development and regulatory...
Continue Reading
Imported Drugs: (Possibly) Coming Soon to a State Near You
By James Ravitz, Paul Gadiock, Marissa Hill Daley, Nathan Gray and Karis Jackson on May 16, 2024
Posted In Employee Benefits, Health and Welfare Plans
In recent years, states have been exploring innovative avenues to address rising healthcare costs and ensure access to affordable medication for their residents. One idea gaining traction involves pursuing authorization from the US Food and Drug Administration (FDA) for importation programs under Section 804 of the Federal Food, Drug, and Cosmetic Act (FDCA) to import...
Continue Reading